Grupo Biotoscana Advances Integration of Laboratorio LKM

Feb 04 2016

MONTEVIDEO – – Grupo Biotoscana SL (GBT), a leading specialty pharmaceutical company in Latin America, today announced continued progress in its integration of Laboratorio LKM (LKM) with an enhanced organizational structure and leadership team that combine the best of GBT’s legacy companies. GBT’s December 2015 acquisition of LKM and January 2014 acquisition of United Medical created the first biopharmaceutical company in Latin America with a truly pan-regional presence and focus on specialty pharmaceuticals.

GBT will continue to be led by Mariano García­Valiño as Chief Executive Officer, who has served in this capacity since 2015. The new executive leadership team, which comprises the best executive talent from legacy GBT and LKM, will report directly to Mr. García­Valiño and be responsible for company-wide functions and sub-regional operations. GBT is now organized around three major sub-regions covering all of Latin America and has its corporate headquarters in Montevideo, Uruguay. 

“These developments represent the first steps towards a successful integration with LKM,” said Mariano García­Valiño, Chief Executive Officer of GBT. “We believe our new organizational structure and leadership team will help us capitalize on the numerous opportunities we have before us as a result of our transformative merger with LKM. The leadership team and I look forward to working closely with our investment partners at Advent International and Essex Woodlands to fulfill the promise our newly combined company holds for improving clinical care and patient outcomes throughout Latin America.”

GBT’s new executive leadership team is comprised of:

• Mariano García-Valiño - Chief Executive Officer
• Patricio Rabinovich - EVP and President, South of Latin America (SOLA)
• José Fernando Beltrán - EVP and President, North of Latin America (NOLA)
• Claudio Coracini - EVP and President, Brazil
• Julieta Serna – EVP and Chief Strategy Officer
• Renato De Giorgi – EVP and Chief Business Officer
• Román Saglio – EVP and Chief Marketing Officer
• Eduardo Gomez – EVP and Chief Compliance Officer
• Daniel Flores – EVP and Chief Science Officer
• Diego Moreira – EVP and Chief Financial Officer

All country managers (CMs) in SOLA will report directly to Patricio Rabinovich, while retaining management oversight of Biotoscana, LKM and United Medical operations in their local territories. These CMs are:

• Eduardo Bolt – CM Chile
• Fernando Coral – CM Ecuador
• Diego Debiase – CM Peru
• Gustavo Turano - CM Uruguay & Paraguay
• Juan Duczynski - CM Bolivia

Adrian Beserman, VP SOLA, Ricardo Obendorfer, R&D Director and Mario Malaspina, Manufacturing Director will also report directly to Mr. Rabinovich.

GBT expects to make additional integration announcements at the regional and country level over the course of the next few months.

GBT is controlled by global private equity firm Advent International, with other significant shareholders including Essex Woodlands and a number of private investors. The company operates in some of the fastest-growing geographies in the world, such as Brazil, Colombia, Peru, Chile and Argentina, and focuses on rapidly growing market segments, such as oncology, infectious diseases, hematology, genetic disorders, HIV and rare diseases. GBT will seek to capitalize on this significant opportunity by further expanding its regional footprint, diversifying its product portfolio through in-licensing and proprietary R&D and pursuing additional mergers and acquisitions.

About GBT

Grupo Biotoscana (GBT) is a leading biopharmaceutical company in Latin America with a truly pan-regional presence and focus on specialty pharmaceuticals. GBT has revenue of US$250 million, with operating companies in 10 countries throughout the region and a strong combination of world-class licensed products and proprietary specialty branded generics. GBT markets leading brands in the fields of high-complexity genetic disorders, rare disease, oncology, hematology, infectious disease, HIV and specialty treatments. The company operates under the Biotoscana, United Medical and LKM brands. More information is available at


In the US:
Advent International
Chuck Dohrenwend / Dana Gorman
Abernathy MacGregor (New York)
Tel: +1 212 371 5999
[email protected]

Essex Woodlands
Anne B. DeMaret
Investor Relations
Tel: +1 281 528 1956
[email protected]

In Latin America:
Raul Fagundes Neto / Fernando Marchi
Medialink (São Paulo)
Tel: +55 11 3817 2131
[email protected]